Apellis Pharmaceuticals' stock slides 14% after company gets negative trend vote for eye treatment in Europe
Apellis Pharmaceuticals Inc.'s stock (APLS) tumbled 14% early Thursday, after the company said it's been informed of a negative trend vote on the European marketing authorization application (MAA) for its treatment for an advanced form of age-related macular degeneration that's a leading cause of blindness. The company said it had an oral explanation meeting with the Europe Committee for Medicinal Products for Human Use of the European Medicines Agency on Dec. 13 regarding its MAA for pegcetacoplan as a treatment for geographic atrophy, or GA, and was then informed of the negative trend vote. "Apellis expects the CHMP to adopt a negative opinion at its next meeting, which is scheduled to be held January 22-25, 2024," the company said in a statement. "If a negative opinion is adopted, Apellis plans to appeal the outcome and seek re-examination of the opinion." Jeffrey Eisele, Ph.D and chief development officer at Apellis, said the company was "very disappointed in this outcome and saddened for the millions of GA patients in Europe who have no treatment for this leading cause of blindness." The company's MAA is based on data from late-stage trials at 24 months, which were published in The Lancet. More than 2.5 million people in Europe have GA. Apellis's stock has gained 21.6% in the year to date, while the S&P 500 has gained 22.6%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
12-14-23 0715ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks